Immunovant's IMVT-1402 Fails Primary Endpoint in Lupus Study, Development Halted
IMVT has more than doubled off its 52-week low of $14.58 on elevated volume (1.8× avg).
Summary
Immunovant's proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus (CLE) missed its primary endpoint, failing to achieve statistical significance. The company will stop development of the drug in CLE. Safety and tolerability were favorable, and other clinical timelines remain on track. This is a major setback for a key pipeline asset, likely to pressure the stock. The company's cash position of $797.8M provides runway, but the failure removes a near-term catalyst. Watch for management commentary on strategic implications and any impact on the broader IMVT-1402 program.
At the time of this announcement, IMVT was trading at $36.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7B. The 52-week trading range was $14.58 to $45.42. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.